Alcohol use disorder (AUD) affects one in ten Americans. As one of the largest payers of AUD treatment in the United States, Medicaid managed care plays a key role in facilitating access to AUD treatment services and medications. However, little is known about how AUD coverage in Medicaid managed care organizations (MCOs) affects treatment receipt. We examined the relationship between the comprehensiveness of Medicaid MCO plan coverage of AUD treatment and receipt of medications for AUD (MAUD). We used Medicaid claims data from Kentucky (2016–2019); our final analytic sample consisted of 202,230 newly enrolled Medicaid beneficiaries. Kentucky quasi-randomly assigns Medicaid beneficiaries to one of five MCO plans with different AUD treatment coverage. We leveraged the random assignment to MCO plans using a Two-Stage Least Squares/Instrumental Variable (TSLS/IV) approach to estimate the effects of MCO plan comprehensiveness on receipt of MAUD. Diagnosis with AUD and receipt of MAUD was relatively uncommon— only 0.5 % of Medicaid beneficiaries were diagnosed with AUD and received MAUD across all plans. Results showed that for each additional AUD treatment modality covered, the probability of receiving MAUD increased by 6.7 % relative to the mean [mean: 0.5 %; difference per additional service/MAUD (in percentage points): 0.033; p < 0.05]. Expanding coverage in the least comprehensive MCO plan to match the most comprehensive plan would increase the probability of receiving MAUD by 47 %. Overall, study findings indicate that when insurance plans cover a broader array of AUD treatment services and medications, patients are more likely to receive MAUD.
Introduction: Opioid-related mortality continues to claim tens of thousands of American lives annually. Medicaid plays an outsized role in financing opioid use disorder (OUD) treatment, paying for almost 40% of all Americans who received OUD treatment in 2017. Methods: Using Medicaid T-MSIS Analytic Files data and a novel data set of Medicaid managed care organization (MCO) plan coverage, we examined the relationship between comprehensiveness of benefits for OUD treatment provided by Medicaid MCO plans and the likelihood of OUD diagnosis and medications for OUD (MOUD) receipt among newly enrolled Medicaid beneficiaries in Kentucky. We use two stage least squares to adjust for MCO plan choice that may be correlated with individual OUD risk or individual demand for OUD treatment. Results: Our findings show that Medicaid beneficiaries assigned to MCO plans with more comprehensive OUD benefits are more likely to be diagnosed with OUD and to receive MOUD. Conclusion: These results suggest that increasing Medicaid MCO plan coverage to include a broader array of OUD treatment services and medications may be an effective strategy for increasing both OUD diagnosis and MOUD receipt, which is crucial for combating the ongoing opioid epidemic.